(Q37646434)

21 August 2017

CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions (English)

1 reference

21 August 2017

0 references

0 references

0 references

1 reference

7

Anne H Cross

1 reference

21 August 2017

Enrique Alvarez

1

1 reference

21 August 2017

Laura Piccio

2

1 reference

21 August 2017

Robert J Mikesell

3

1 reference

21 August 2017

Eric C Klawiter

4

1 reference

21 August 2017

Becky J Parks

5

1 reference

21 August 2017

Robert T Naismith

6

1 reference

21 August 2017

language of work or name

1 reference

15 January 2013

1 reference

Multiple Sclerosis Journal

21 August 2017

1 reference

21 August 2017

19

1 reference

21 August 2017

9

1 reference

21 August 2017

1204-1208

1 reference

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.

21 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3959125

Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3959125

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3959125

Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3959125

Revised diagnostic criteria for neuromyelitis optica

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3959125

Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3959125

Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3959125

Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3959125

A prospective study on the role of CXCL13 in Lyme neuroborreliosis

1 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23322500

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Cerebrospinal fluid levels of CXCL13 are elevated in neuromyelitis optica

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23322500

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1177/1352458512473362

1 reference

21 August 2017

1 reference

21 August 2017

PubMed publication ID

23322500

1 reference